Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quillichew ER in 4-5 year olds with ADHD
NCT03580005Phase 4Withdrawn
- Sponsor
- Pfizer
- Start
- Oct 2018
- Primary completion
- Oct 2021
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, double-blind trial of methylphenidate in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Pfizer. Primary endpoints: Incidence of treatment emergent adverse events at 6 months and Attention Deficit Hyperactivity Rating Scale - IV Preschool-Home Version at 6 weeks. Planned start Oct 2018; status: withdrawn.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT03580005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03580005.